Plain-English translation of NCT07409103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ELV001, a new medication designed to help people with rheumatoid arthritis whose disease isn't controlled well enough by their current treatments. You would take this medication in addition to the treatments you're already on. The study will test three different doses of the medication against a placebo to see which is safest and most effective.
Many people with rheumatoid arthritis don't get enough relief from standard treatments like methotrexate and TNF inhibitors. This trial is exploring whether this new treatment can help those patients by adding an additional option to their current therapy.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for a 4-week screening period, then be randomly assigned to receive either the new medication at one of three doses or a placebo while continuing your current treatments. You would take the medication once daily for 12 weeks in the main study period, then have the option to continue for another 12 weeks. The entire process takes about 6 months, including follow-up visits to monitor your health and disease activity.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States